Transthyretin amyloid disease (ATTR) is a progressive, life-threatening condition caused when the protein transthyretin (TTR) breaks apart and aggregates in the heart and other organs. One of the most common treatments, a drug called tafamidis, works by helping TTR stay intact—slowing how it normally unfolds and aggregates.